Skip to main content
Log in

Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery

  • Full-length paper
  • Published:
Molecular Diversity Aims and scope Submit manuscript

Abstract

Natural product analogs are significant sources for therapeutic agents. To capitalize efficiently on the effective features of naturally occurring substances, a natural product-based library production platform has been devised at Aurigene for drug lead discovery. This approach combines the attractive biological and physicochemical properties of natural product scaffolds, provided by eons of natural selection, with the chemical diversity available from parallel synthetic methods. Virtual property analysis, using computational methods described here, guides the selection of a set of natural product scaffolds that are both structurally diverse and likely to have favorable pharmacokinetic properties. The experimental characterization of several in vitro ADME properties of twenty of these scaffolds, and of a small set of designed congeners based upon one scaffold, is also described. These data confirm that most of the scaffolds and the designed library members have properties favorable to their utilization for creating libraries of lead-like molecules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

ADME:

absorption-distribution-metabolism-excretion

BCUT:

Burden-Chemical Abstract Services–University of Texas

DMSO:

dimethylsulfoxide

e-ADME:

early ADME

HPLC/UV:

high performance liquid chromatography monitored by ultraviolet absorbance

LC-MS:

liquid chromatography–mass spectrometry

MDCK:

Madin-Darby canine kidney

NCI:

National Cancer Institute

PBS:

phosphate buffered saline

PSA:

polar surface area

TEER:

transepithelial electrical resistance

References

  1. Samuelsson, G., Drugs of natural origin, Swedish Pharmaceutical Society, Stockholm, Sweden, 1991.

    Google Scholar 

  2. Buss, A.D., Cox, B. and Waigh, R.D., Natural products as leads for new pharmaceuticals, In Abraham, D.J. (Ed), Burger’s Medicinal Chemistry and Drug Discovery, Sixth Edition, Vol. 1, Wiley Interscience, New York, 2003, pp. 847–900.

    Google Scholar 

  3. Newman, D.J., Cragg, G.M. and Snader, K.M., Natural products as sources of new drugs over the period 1981–2002, J. Nat. Prod., 66 (2003) 1022–1037.

    Google Scholar 

  4. Feher, M. and Schmidt, J.M., Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry, J. Chem. Inf. Comput. Sci., 43 (2003) 218–227.

    Google Scholar 

  5. Henkel, T., Brunne, R.M., Muller, H. and Reichel, F., Statistical investigation into the structural complementarity of natural products and synthetic compounds, Angew. Chem. Int., 38 (1999) 643–647.

    Google Scholar 

  6. Rouhi, A.M., Rediscovering natural products, Chem. Eng. News, 81 (2003) 77–91.

    Google Scholar 

  7. Rouhi, A.M., Betting on natural products for cures, Chem. Eng. News, 81 (2003) 93–103.

    Google Scholar 

  8. Rouhi, A.M., Moving beyond natural products, Chem. Eng. News, 81 (2003) 104–107.

    Google Scholar 

  9. Urizar, N.L. and Moore, D.D., Gugulipid: A natural cholesterol-lowering agent, Annu. Rev. Nutr., 23 (2003) 303–313.

    Google Scholar 

  10. Urizar, N.L., Liverman, A.B., Dodds, D.T., Silva, F.V., Ordentlich, P., Yan, Y., Gonzalez, F.J., Heyman, R.A., Mangelsdorf, D.J. and Moore, D.D., A natural product that lowers cholesterol as an antagonist ligand for FXR, Science, 296 (2002) 1703–1706.

    Google Scholar 

  11. van de Waterbeemd, H. and Gifford, E. ADMET in silico modelling: Towards prediction paradise? Nat. Rev. Drug. Discov., 2 (2003) 192–204.

    Google Scholar 

  12. Kennedy, T., Managing the drug discovery/development interface, Drug Discov. Today, 2 (1997) 436–444.

    Google Scholar 

  13. Stoner, C.L., Cleton, A., Johnson, K., Oh, D.M., Hallak, H., Brodfuehrer, J., Surendran, N. and Han, H.K., Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery, Int. J. Pharm., 268 (2004) 241-249.

    Google Scholar 

  14. Yu, H., and Adedoyin, A., ADME-Tox in drug discovery: Integration of experimental and computational technologies, Drug Discov. Today, 8 (2003) 852–861.

    Google Scholar 

  15. Crespi, C.L., Miller, V.P. and Stresser, D.M., Design and application of fluorometric assays for human cytochrome P450 inhibition, Methods Enzymol., 357 (2002) 276–284.

    Google Scholar 

  16. Pearlman, R.S. and Smith, K.M., Metric validation and the receptor-relevant subspace concept, J. Chem. Inf. Comput. Sci., 39 (1999) 28–35.

    Google Scholar 

  17. Diverse Solutions Users Manual version 3.0.1: Laboratory of Molecular Graphics and Theoretical Modeling, University of Texas, Austin,Texas copyrighted 1996, 1997, Distributed by Tripos Inc., 1699 S. Hanley Road, St. Louis, MO 63144 (1996, 1997).

  18. Mason, J.S., Absolute versus relative similarity and diversity, In Dean, P.M., and Lewis, R.A. (Eds) Molecular Diversity in Drug Design, Kluwer Academic Publishers, Dordrecht (1999), pp.88-90.

    Google Scholar 

  19. Holliday, J.D., Ranade, S.S. and Willett, P., A fast algorithm for selecting sets of dissimilar molecules from large chemical databases, Quant. Struct.-Act. Relat., 14 (1995) 501–506.

    Google Scholar 

  20. Lipinski, C.A., Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Methods, 44 (2000) 235–249.

    Google Scholar 

  21. Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W. and Kopple, D.K., Molecular properties that influence oral bioavailability of drug candidates, J. Med. Chem., 45 (2002) 2615–2623.

    Google Scholar 

  22. Irvine, J.D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J.W., Selick, H.E. and Grove, J.R., MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening, J. Pharm. Sci., 88 (1999) 28–33.

    Google Scholar 

  23. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C.A. and Sugiyama, Y., Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther., 73 (1997) 147–171.

    Google Scholar 

  24. Mandagere, A.K., Thompson, T.N. and Hwang, K.K., Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates, J. Med. Chem., 45 (2002) 304-311.

    Google Scholar 

  25. Palm, K., Stenberg, P., Luthman, K. and Artursson, P., Polar molecular surface properties predict the intestinal absorption of drugs in humans, Pharm. Res., 14 (1997) 568–571.

    Google Scholar 

  26. Clark, D.E., Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption, J. Pharm. Sci., 88 (1999) 807-814.

    Google Scholar 

  27. Yan, Z. and Caldwell, G.W., Metabolism profiling, and cytochrome P450 inhibition and induction in drug discovery, Curr. Top. Med. Chem., 1 (2001) 403–425.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. W. Hardy.

Additional information

These authors have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Samiulla, D., Vaidyanathan, V.V., Arun, P.C. et al. Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery. Mol Divers 9, 131–139 (2005). https://doi.org/10.1007/s11030-005-1297-7

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11030-005-1297-7

Keywords

Navigation